[Show abstract][Hide abstract] ABSTRACT: Prostate cancer is the second most common cancer in men worldwide. Although the aetiology of this disease remains largely unclear, several lines of evidence suggest that oxidative stress plays a role in prostate carcinogenesis. The antioxidant enzyme glutathione peroxidase 1 (GPX1) is part of the enzymatic antioxidant defence, preventing oxidative damage to DNA, proteins and lipids by detoxifying hydrogen and lipid peroxides that may contribute to prostate cancer development. Some studies indicate an association between GPX1 Pro198Leu polymorphism and an increased risk of cancer. The purpose of the present study was to determine the possible association of GPX1 Pro198Leu polymorphism and erythrocyte GPX activity with the risk of developing prostate cancer and to clarify whether erythrocyte GPX activity levels were correlated with the GPX1 Pro198Leu genotype in the Turkish population. The GPX1 Pro198Leu genotype was determined in 33 prostate cancer patients and 91 control individuals. As evident from our results, there was no difference between genotype and/or allele frequencies in prostate cancer patients and controls. No significant difference was found in GPX1 genotype or allele frequency between aggressive and non-aggressive prostate cancer patients. It can be suggested with these findings that individual susceptibility of prostate cancer may be modulated by GPX1 polymorphism, but it needs further studies.
Human & Experimental Toxicology 06/2011; 31(1):24-31. · 1.31 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: We undertook the present study to develop a validated HPLC method for the determination of malondialdehyde (MDA) levels and to use this method for determination of MDA levels in patients with prostate cancer and benign prostatic hyperplasia. MDA levels were estimated in the erythrocyte and plasma sample of the 25 non-metastatic prostate cancer patients, 36 benign prostatic hyperplasia (BPH) patients and 24 age- and sex-matched healthy subjects (controls) in HP Chromatographic systems consisting of a Model Agilent 1100 Series. We report a very rapid and simple isocratic reversed-phase HPLC separation of MDA in normal human plasma and erythrocytes without previous purification of the MDA-TBA complex. All validation parameters were performed in our methods. Using this methods we have found elevated MDA in the plasma and erythrocyte of the prostate cancer group as compared to controls and BPH group. We have improved and validated an analytical HPLC method for determination of MDA in plasma and erythrocyte, which is simple to perform and having high sensitivity, specificity and substantial improvement in column life. This method has been successfully applied to determination of MDA levels in prostate cancer patients and offers an oportunity to further characterize the role of oxidative injury in the pathogenesis of this disease specifically.
Journal of Liquid Chromatography & Related Technologies 01/2007; 30(16):2435-2444. · 0.57 Impact Factor